KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Depreciation & Amortization (CF): 2011-2024

Historic Depreciation & Amortization (CF) for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to $100,000.

  • Esperion Therapeutics' Depreciation & Amortization (CF) changed negligibly% to $26,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $143,000, marking a year-over-year increase of 37.50%. This contributed to the annual value of $100,000 for FY2024, which is 50.00% down from last year.
  • Latest data reveals that Esperion Therapeutics reported Depreciation & Amortization (CF) of $100,000 as of FY2024, which was down 50.00% from $200,000 recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Depreciation & Amortization (CF) ranged from a high of $612,000 in FY2021 and a low of $100,000 during FY2024.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $200,000 (2023), whereas its average is $266,667.
  • Per our database at Business Quant, Esperion Therapeutics' Depreciation & Amortization (CF) spiked by 71.47% in 2020 and then plummeted by 60.00% in 2023.
  • Yearly analysis of 5 years shows Esperion Therapeutics' Depreciation & Amortization (CF) stood at $547,000 in 2020, then grew by 11.88% to $612,000 in 2021, then declined by 18.30% to $500,000 in 2022, then tumbled by 60.00% to $200,000 in 2023, then slumped by 50.00% to $100,000 in 2024.